


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (PREVIOUSLY PRESENTED) A compound of formula



wherein W^6 and X^6 are $-CR^1R^2$; Y^5 is selected from the group consisting of $-(CH_2)_a-$ CONH-Bm, $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$, $-(CH_2)_a-NHCO-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$, $-(CH_2)_a-N(R^3)-(CH_2)_b-CONH-Bm$, $(CH_2)_a-N(R^3)-(CH_2)_c-NHCO-Bm$, $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$, $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-CONH-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-NHCO-Bm$, $-(CH_2)_a-NR^3R^4$, and $-CH_2-(CH_2OCH_2)_b-CH_2NR^3R^4$; Z^5 is selected from the group consisting of $-(CH_2)_a-$ CONH-Dm, $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$, $-(CH_2)_a-NHCO-Dm$, $-CH_2-(CH_2OCH_2)_b-$

CH2-NHCO-Dm, -(CH2)a-N(R3)-(CH2)b-CONH-Dm, (CH2)s-N(R3)-(CH2)c-NHCO-Dm, -(CH2)a-N(R3)-CH2-(CH2OCH2)b-CH2-CONH-Dm, -(CH2)s-N(R3)-CH2-(CH2OCH2)b-CH2-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)s-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-(CH2)a-NHCO-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-CONH-Dm, -CH2-(CH2OCH2)b-CH2-N(R3)-CH2-(CH2OCH2)d-NHCO-Dm, -(CH2)s-NR3R4, and -CH2-(CH2OCH2)b-CH2NR3R4; A_3 is a single or a double bond; B_3 , C_3 , and D_3 are independently selected from the group consisting of $-O-$, $-S-$, $-Se-$, $-P-$, $-CR^1R^2$, $-CR^1$, alkyl, NR^3 , and $-C=O$; A_3 , B_3 , C_3 , and D_3 may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a_5 vary from 0 to 5; R^1 to R^4 , and R^{68} to R^{66} are independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_6-C_{20} aryl, C_1-C_{10} alkoxy, C_1-C_{10} polyalkoxyalkyl, C_1-C_{20} polyhydroxyalkyl, C_6-C_{20} polyhydroxyaryl, C_1-C_{10} aminoalkyl, cyano, nitro, halogen, saccharide, peptide, -CH2-(CH2OCH2)b-CH2-OH, -(CH2)a-CONH-Bm, -CH2-(CH2OCH2)b-CH2-CONH-Bm, -(CH2)a-NHCO-Bm, -CH2-(CH2OCH2)b-CH2-NHCO-Bm, and -CH2-(CH2OCH2)b-CO2H; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100.


2. (CURRENTLY AMENDED) The compound of claim 1 wherein W⁵ and X⁵ are independently selected from the group consisting of -C(CH₃)₂, -C((CH₂)_aOH)CH₃, -C((CH₂)_aOH)₂, -C((CH₂)_aCO₂H)CH₃, -C((CH₂)_aCO₂H)₂, -C((CH₂)_aNH₂)CH₃, C((CH₂)_aNH₂)₂, C((CH₂)_aNR³R⁴)₂; Y⁵ is selected from the group consisting of -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; Z⁵ is selected from the group consisting of -(CH₂)_a-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-NHCO-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; A₃ is a single or a double bond; B₃, C₃, and D₃ are independently selected from the group consisting of -O-, -S-, NR³, (CH₂)_a-CR¹R², and -CR¹; A₃, B₃, C₃, and D₃ may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a₅ vary from 0 to 3; R¹ to R⁴, and R⁵⁸ to R⁶⁶ are independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₅-C₁₂ aryl, C₁-C₁₀ alkoxy, C₁-C₁₀ polyhydroxyalkyl, C₅-C₁₂ polyhydroxyaryl, C₁-C₁₀ aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units, -CH₂(CH₂OCH₂)_b-CH₂-OH, -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, and -CH₂-(CH₂OCH₂)_b-CO₂H; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex,

and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

3. (CURRENTLY AMENDED) The compound of claim 2 wherein each of W⁵ and X⁵ is C((CH₂)OH)₂-C(CH₃)₂; Y⁵ is -(CH₂)₂-CONH-Bm; Z⁵ is -(CH₂)₂-CONH-Dm; A₃ is a single bond; A₃, B₃, C₃, and D₃ together form a 6-membered carbocyclic ring; a₅ is 1; R⁵⁸ is galactose; each R⁵⁹ to R⁶⁶ is hydrogen; Bm is Octreotide; Dm is bombesin (7-14).

4. (PREVIOUSLY PRESENTED) A method for performing a diagnostic or therapeutic procedure comprising

administering to an individual an effective amount of the compound of formula



wherein W⁵ and X⁵ are -CR¹R²; Y⁵ is selected from the group consisting of -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -(CH₂)_a-N(R³)-(CH₂)_b-CONH-Bm, (CH₂)_a-N(R³)-(CH₂)_c-NHCO-Bm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-NHCO-Bm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; Z⁵ is selected from the group consisting of -(CH₂)_a-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-NHCO-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-N(R³)-(CH₂)_b-CONH-Dm, (CH₂)_a-N(R³)-(CH₂)_c-NHCO-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-(CH₂)_a-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-NHCO-Dm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; A₃ is a single or a double bond; B₃, C₃, and D₃ are independently selected from the group consisting of -O-, -S-, -Se-, -P-, -CR¹R², -CR¹, alkyl, NR³, and -C=O; A₃, B₃, C₃, and D₃ may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a₅ vary from 0 to 5; R¹ to R⁴, and R⁵⁸ to R⁶⁶ are independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₅-C₂₀ aryl, C₁-C₁₀ alkoxy, C₁-C₁₀ polyalkoxyalkyl, C₁-C₂₀ polyhydroxyalkyl, C₅-C₂₀

polyhydroxyaryl, C₁-C₁₀ aminoalkyl, cyano, nitro, halogen, saccharide, peptide, -CH₂(CH₂OCH₂)_b-CH₂-OH, -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, and -CH₂-(CH₂OCH₂)_b-CO₂H; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100, and a pharmaceutically acceptable carrier or excipient to form a composition,

activating the compound using light, and
performing the diagnostic or therapeutic procedure.

5. (CURRENTLY AMENDED) The method of claim 4 comprising administering to an individual an effective amount of the compound wherein W⁵ and X⁵ are independently selected from the group consisting of -C(CH₃)₂, -C((CH₂)_aOH)CH₃, -C((CH₂)_aOH)₂, -C((CH₂)_aCO₂H)CH₃, -C((CH₂)_aCO₂H)₂, -C((CH₂)_aNH₂)CH₃, C((CH₂)_aNH₂)₂, C((CH₂)_aNR³R⁴)₂; Y⁶ is selected from the group consisting of -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -(CH₂)_a-NR³R⁴, and -CH₂-(CH₂OCH₂)_b-CH₂-NR³R⁴; Z⁵ is selected from the group consisting of -(CH₂)_a-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-NHCO-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-NR³R⁴, and

-CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; A₃ is a single or a double bond; B₃, C₃, and D₃ are independently selected from the group consisting of -O-, -S-, NR³, (CH₂)_a-CR¹R², and -CR¹; A₃, B₃, C₃, and D₃ may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a₅ vary from 0 to 3; R¹ to R⁴, and R⁶⁸ to R⁸⁶ are independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₅-C₁₂ aryl, C₁-C₁₀ alkoxy, C₁-C₁₀ polyhydroxyalkyl, C₅-C₁₂ polyhydroxyaryl, C₁-C₁₀ aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units, -CH₂(CH₂OCH₂)_b-CH₂-OH, -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, and -CH₂-(CH₂OCH₂)_b-CO₂H; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

6. (CURRENTLY AMENDED) The method of claim 5 comprising administering to an individual an effective amount of the compound wherein each W⁵ and X⁵ is $\text{E}(\text{CH}_2\text{OH})_2-\text{C}(\text{CH}_3)_2$; Y⁵ is -(CH₂)₂-CONH-Bm; Z⁵ is -(CH₂)₂-CONH-Dm; A₃ is a single bond; A₃, B₃, C₃, and D₃ together form a 6-membered carbocyclic ring; a₅ is 1; R⁵⁸ is galactose; each R⁵⁹ to R⁸⁶ is hydrogen; Bm is Octreotide; Dm is bombesin (7-14).

7. (ORIGINAL) The method of claim 4 wherein said procedure uses light of wavelength in the region of 350-1300 nm.
8. (ORIGINAL) The method of claim 4 wherein the diagnostic procedure is optical tomography.
9. (ORIGINAL) The method of claim 4 wherein the diagnostic procedure is fluorescence endoscopy.
10. (ORIGINAL) The method of claim 4 further comprising monitoring a blood clearance profile of said compound by fluorescence, absorbance or light scattering wherein light of wavelength in the region of 350-1300 nm is used.
11. (ORIGINAL) The method of claim 4 wherein said procedure further comprises a step of imaging and therapy wherein said imaging and therapy is selected from the group consisting of absorption, light scattering, photoacoustic and sonofluorescence technique.
12. (ORIGINAL) The method of claim 4 wherein said procedure is for diagnosing atherosclerotic plaques and blood clots.
13. (ORIGINAL) The method of claim 4 wherein said procedure comprises administering localized therapy.


14. (ORIGINAL) The method of claim 4 wherein said therapeutic procedure comprises photodynamic therapy.

15. (ORIGINAL) The method of claim 4 wherein said therapeutic procedure comprises laser assisted guided surgery for the detection of micrometastases.

16. (PREVIOUSLY PRESENTED) The method of claim 4 further comprising adding a biocompatible organic solvent to the compound at a concentration of one to fifty percent to the composition to prevent *in vivo* or *in vitro* fluorescence quenching.

17. (ORIGINAL) The method of claim 16 wherein said compound is dissolved in a medium comprising one to fifty percent dimethyl sulfoxide.

18. (PREVIOUSLY PRESENTED) A composition comprising a cyanine dye bioconjugate of formula



wherein W⁵ and X⁵ are -CR¹R²; Y⁵ is selected from the group consisting of -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -(CH₂)_a-N(R³)-(CH₂)_b-CONH-Bm, (CH₂)_a-N(R³)-(CH₂)_c-NHCO-Bm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-N(R³)-CH₂-(CH₂OCH₂)_d-NHCO-Bm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; Z⁵ is selected from the group consisting of -(CH₂)_a-CONH-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-NHCO-Dm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-N(R³)-(CH₂)_b-CONH-Dm, (CH₂)_a-N(R³)-(CH₂)_c-NHCO-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Dm, -(CH₂)_a-N(R³)-CH₂-(CH₂OCH₂)_b-CH₂-CONH-Dm, -(CH₂)_a-NR³R⁴, and -CH₂(CH₂OCH₂)_b-CH₂NR³R⁴; A₃ is a single or a double bond; B₃, C₃, and D₃ are independently selected from the group consisting of -O-, -S-, -Se-, -P-, -CR¹R², -CR¹, alkyl, NR³, and -C=O; A₃, B₃, C₃, and D₃ may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a₅ vary from 0 to 5; R¹ to R⁴, and R⁵⁸ to R⁶⁶ are independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl,

C_5-C_{20} aryl, C_1-C_{10} alkoxy, C_1-C_{10} polyalkoxyalkyl, C_1-C_{20} polyhydroxyalkyl, C_5-C_{20} polyhydroxyaryl, C_1-C_{10} aminoalkyl, cyano, nitro, halogen, saccharide, peptide, $-CH_2(CH_2OCH_2)_b-CH_2-OH$, $-(CH_2)_a-CONH-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$, $-(CH_2)_a-NHCO-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$, and $-CH_2-(CH_2OCH_2)_b-CO_2H$; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100, and a pharmaceutically acceptable carrier or excipient.

19. (CURRENTLY AMENDED) The composition of claim 18 wherein W^5 and X^5 are independently selected from the group consisting of $-C(CH_3)_2$, $-C((CH_2)_aOH)CH_3$, $-C((CH_2)_aOH)_2$, $-C((CH_2)_aCO_2H)CH_3$, $-C((CH_2)_aCO_2H)_2$, $-C((CH_2)_aNH_2)CH_3$, $C((CH_2)_aNH_2)_2$, $C((CH_2)_aNR^3R^4)_2$; Y^6 is selected from the group consisting of $-(CH_2)_a-CONH-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$, $-(CH_2)_a-NHCO-Bm$, $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$, $-(CH_2)_a-NR^3R^4$, and $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$; Z^5 is selected from the group consisting of $-(CH_2)_a-CONH-Dm$, $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$, $-(CH_2)_a-NHCO-Dm$, $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Dm$, $-(CH_2)_a-NR^3R^4$, and $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$; A_3 is a single or a double bond; B_3 , C_3 , and D_3 are independently selected from the group consisting of $-O-$, $-S-$, NR^3 , $(CH_2)_a-CR^1R^2$,

and -CR¹; A₃, B₃, C₃, and D₃ may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a₅ vary from 0 to 3; R⁷ to R⁴, and R⁶⁸ to R⁶⁶ are independently selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₅-C₁₂ aryl, C₁-C₁₀ alkoxy, C₁-C₁₀ polyhydroxyalkyl, C₅-C₁₂ polyhydroxyaryl, C₁-C₁₀ aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units, -CH₂(CH₂OCH₂)_b-CH₂-OH, -(CH₂)_a-CONH-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-CONH-Bm, -(CH₂)_a-NHCO-Bm, -CH₂-(CH₂OCH₂)_b-CH₂-NHCO-Bm, -(CH₂)_a-OH and -CH₂-(CH₂OCH₂)_b-CO₂H; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

20. (CURRENTLY AMENDED) The composition of claim 19 wherein each of W⁵ and X⁶ is $\text{G}((\text{CH}_2)\text{OH})_2-\text{C}(\text{CH}_3)_2$; Y⁵ is -(CH₂)₂-CONH-Bm; Z⁵ is -(CH₂)₂-CONH-Dm; A₃ is a single bond; A₃, B₃, C₃, and D₃ together form a 6-membered carbocyclic ring; a₅ is 1; R⁵⁸ is galactose; each R⁵⁹ to R⁶⁶ is hydrogen; Bm is Octreotide; Dm is bombesin (7-14), and a pharmaceutically acceptable carrier or excipient.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.